Our teams comprise the brightest minds who are working to make a remarkable impact.
ABBVIE IN ONCOLOGY: DEFYING THE STATUS QUO

At AbbVie, we have a dynamic, entrepreneurial culture that encourages risk-taking and we’re looking for passionate, courageous and persistent individuals to approach complex challenges in new ways.

The best science comes from the best scientists. Our researchers explore novel mechanisms of action and administration to disrupt cancer development and growth across multiple tumor types. It is this ongoing research that demonstrates our relentless pursuit in striving to outsmart cancer, together.

The pioneering spirit of our commercial team supports our rapidly advancing pipeline, bringing new products to launch and telling their story on a global stage.

Our teams comprise the brightest minds who are working to make a remarkable impact on people affected by cancer —improving the standard of care to help patients live better and longer.

“Somewhere out there is a person who has no inclination they will desperately need what we are working on today. They will likely never see our faces or know our names but we might change their reality in a meaningful way. That is worthwhile and exciting work.”

— Byran Litton, Vice President, US Commercial Oncology

abbvie.com/onc-jobs
We’re looking for the brightest and best to come join our team in oncology.
ABBVIE: TAKE A CLOSER LOOK

AbbVie is striving to discover and develop medicines that deliver transformational improvements in cancer treatment by uniquely combining our deep knowledge in core areas of biology with cutting-edge technologies and by working together with our partners — scientists, clinical experts, industry peers, advocates, and patients.

Read on to get a full view of AbbVie’s work in oncology: Our history, our values and the aggressive mission we’ve set forth, striving to outsmart cancer, together. We’re looking for the brightest and best to come join our team in oncology.

“I have watched, sometimes enviously, for a number of years as AbbVie has grown its portfolio and pipeline and established itself as an oncology company. Therefore I was excited when I was approached to join the company. To say that I am looking forward to being part of what promises to be a fantastic journey is an understatement.”

— Neil Gallagher, Vice President and Head, Global Oncology Development
REMARKABLE IMPACT ON PEOPLE’S LIVES.

At AbbVie, our mission is to have a remarkable impact on people’s lives.

“We are focused on delivering treatments in oncology that will have a transformative impact on the lives of people affected by cancer. It’s going to take all of us working together to make a difference in the fight against cancer.”

– Michael E. Severino, M.D., Chief Scientific Officer

Michael E. Severino, M.D.
Executive Vice President, Research & Development and Chief Scientific Officer

Dr. Severino is the Executive Vice President, Research & Development and Chief Scientific Officer of AbbVie. He previously served as Senior Vice President, Global Development and Corporate Chief Medical Officer at Amgen, Inc. Dr. Severino held other management roles at Amgen, Inc., including Vice President, Global Development, and Vice President, Therapeutic Area Head, General Medicine and Inflammation Global Clinical Development. He joined AbbVie in 2014.
STRAVING TO OUTSMART CANCER. TOGETHER.

Our journey began more than 20 years ago, when a group of scientists wanted to better understand the process of apoptosis. This is when our researchers first defined B-cell lymphoma (BCL-2) family protein interactions. A few years later, the first peer-reviewed journal on BCL-2 inhibition was published, and the research became the basis for development of inhibitors of the BCL-2 proteins as potential anti-cancer therapeutics.

“We have a strong commitment to oncology and you can see that in the depth of our pipeline. We’re looking for the right talent to help – experts – who can make an immediate impact.”

– Tom Spalding, Vice President, Oncology Global Marketing and Commercial Operations

COMMERCIAL SUCCESS AND DEVELOPING OPPORTUNITIES

Speed is of the essence when addressing significant unmet need. AbbVie aims to expedite the clinical development process for oncology treatments through the use of streamlined clinical trial designs. With a growing sales force and a team of oncology leaders and scientists who are the best in their field, AbbVie is invested in revolutionizing the oncology space.
Our scientists are working to develop the newest and most effective ways to treat cancer, and our commercial team in Lake County is leading the effort to build awareness and is preparing to bring these medicines to the market once they are approved. It’s an exciting time to be part of AbbVie’s oncology business.”

— Elaine K. Sorg, Vice President, U.S. Immunology & Oncology
**OUR ONCOLOGY JOURNEY**

- 3 Medicines in the market
- 3 Programs in late-stage clinical development
- 8 Breakthrough designations by the FDA
- 20+ Programs in pre-clinical development and Phase 1
- 200+ Global clinical trials conducted
- 20+ Different tumor types being researched
- 47+ Countries around the world conducting AbbVie clinical studies
- 21 Primary research and manufacturing facilities around the world
- 5 AbbVie R&D sites in the U.S. focused on oncology
OUR RESEARCH SITES

We have world-class oncology research and development facilities focused on delivering transformative new approaches in the fight against cancer.

We have more than 50 sites engaged in oncology research worldwide with specific knowledge and understanding of local needs and opportunities. The majority of our oncology research and development is led by five key U.S. AbbVie centers located in Lake County, Illinois; Redwood City, California; South San Francisco, California; Sunnyvale, California; and Worcester, Massachusetts.

AbbVie Lake County Facilities – North Chicago, Illinois
9,000 Employees

Lake County, Illinois, is home to a world-class Oncology R&D facility focused on delivering transformative therapies in the fight against cancer. Lake County personnel have expertise in all aspects of drug discovery and development. Key areas of specialization include small molecule and biologic-based drug discovery in the areas of apoptosis, antibody drug conjugates (ADCs), Immuno-Oncology (I-O), and T-cell receptor therapeutics. There also exists a full spectrum of enabling technologies in protein sciences, target-enabling technologies, process chemistry, imaging, and translational biomarkers. Based on the state-of-the-art discovery, preclinical research, drug manufacturing, and clinical development capabilities, breakthrough cancer treatments are made possible for patients. Venetoclax, which is currently on the market (and partnered with Genentech), was discovered and developed at Lake County. The Lake County pipeline also includes multiple promising cancer treatments in later-stage clinical trials: Depatux-M (ADC selectively targeting EGFR), Veliparib (PARP inhibitor), and Teliso-V (cMET-ADC). Phase 1 clinical trial assets include ABBV-075 (BET inhibitor) and ABBV-621 (TRAIL-R agonist), as well as several ADC programs being developed across various solid tumor indications. There are also multiple (~10) pre-clinical programs in earlier stages of R&D that cover areas in apoptosis, ADCs, and I-O.

AbbVie – Worcester, Massachusetts
900+ Employees

While research is happening at multiple sites around the world, Worcester has played a uniquely important role in making AbbVie what it is today, with a long and successful history in the area of biologics. Abbott bought the Worcester facility from BASF in 2000, when the latter was developing a promising rheumatoid arthritis drug, Humira. Humira is now the world’s best-selling drug.

Pharmacyclics, an AbbVie Company – Sunnyvale, California
900+ Employees

Pharmacyclics, an AbbVie Company, is the industry leader in the development and delivery of oral Bruton’s tyrosine kinase (BTK) inhibitors that target the over-activation of B cells that may lead to malignancies and immune-mediated disorders. Pharmacyclics clinical and research professionals combine novel covalent inhibitor technology with knowledge of systemic immunobiology to develop innovative small-molecule drugs that treat cancer and immune-mediated diseases. Pharmacyclics is located in Sunnyvale, California, once of several cities comprising Silicon Valley.

Scientists work on drugs AbbVie has enrolled in clinical trials with the U.S. Food and Drug Administration, as well as on research into new molecules that might one day become the company’s next blockbuster drug.
AbbVie Stemcentrx LLC – South San Francisco, California
240 Employees

AbbVie Stemcentrx LLC leverages proprietary platforms to identify and functionally characterize cancer stem cells (CSCs), which are the sub-population of cancer cells that lead to tumor growth and metastases. This focus enables the discovery of novel CSC-associated oncology targets.

Stemcentrx scientists are experts in using these leads to develop clinical candidate antibody-drug conjugates (ADCs) directed to CSC. Their expertise in protein engineering, preclinical validation in patient derived xenograft models, and in ADC manufacturing and development allows for accelerated development of first-in-class therapeutics.

The Stemcentrx pipeline includes rovalpituzumab tesirine (Rova-T), an ADC in Ph3 for the treatment of DLL3-positive neuroendocrine tumors, five early phase clinical programs across various solid tumor indications, and many more biologics in earlier stages of research and development.

AbbVie Stemcentrx has state-of-the-art discovery, preclinical research and clinical manufacturing and development capabilities collocated under one roof in the heart of the AbbVie West Coast biotech hub, in South San Francisco, CA.

AbbVie – Redwood City, California
215 Employees

AbbVie Redwood City is a state of the art R&D center for AbbVie, located in the San Francisco Bay Area that is focused on the discovery and development of novel cancer therapies. Key areas of specialization include Immuno-Oncology Research and Development, protein engineering and translational biomarkers. AbbVie’s oncology experts at this site are passionate about applying their cross-functional expertise in the areas of discovery biology, protein engineering, biologics manufacturing, pre-clinical development, translational sciences and clinical development to bring breakthrough cancer treatments to patients. Some of the products discovered and developed at this site that are currently on the market include: Empliciti™ (elotuzumab; in collaboration with BMS for the treatment of multiple myeloma). Also, in the last four years, our teams have created a promising pipeline of oncology treatments that includes seven clinical programs: Teliso-V (cMET-ADC), ABT-165 (DLL4xVEGF mAb), ABBV-085 (LRRC15-ADC), ABBV-428 (I-O mAb), ABBV-927 (I-O mAb), ABBV-368 (I-O mAb), and ABBV-181 (I-O mAb), and multiple I-O pre-clinical and discovery programs. Furthermore, in addition to the scientific expertise that resides at AbbVie Redwood City, key business functions such as Global Commercial Development, Business Development and AbbVie Ventures are also based at this site.
“Great science takes great talent. By investing in groundbreaking science, technology and—most importantly—dedicated researchers, AbbVie generates the insights necessary to deliver a new wave of oncology treatments. I’m proud of the important work our teams are doing every day to help better the lives of people living with cancer and their loved ones.”

— Thomas Hudson M.D., Vice President, Oncology Discovery and Early Development
To make a remarkable impact on the lives of people with cancer, we are focused on delivering transformative therapies addressing the unmet needs in a selected set of debilitating and widespread cancers.

**System Biology**

System biology is computational modeling of multidimensional biological systems that cannot be explained according to direct one-to-one interactions. We apply system biology to inductive bottom up observation of human phenomena to generate and test hypotheses that prioritize clinical relevance and impact of a given research project. In immuno-oncology, we utilize this strategy to identify the cause for the resistance of cancer to immunotherapy. The latter is a multifactorial phenomenon that does not follow a linear cause/effect process but rather a chaotic mix of determinants that can only be dissected through nonlinear pattern recognition similar to the way the weather forecast is assembled.
AbbVie’s Primary Disease Focus in Oncology

**Hematology**
- Chronic Lymphocytic Leukemia (CLL)
- Non-Hodgkin’s Lymphoma (NHL)
- Acute Myeloid Leukemia (AML)

**Solid Tumors**
- Lung Cancer
  - Non-Small Cell Lung Cancer (NSCLC)
  - Small Cell Lung Cancer (SCLC)
- Breast Cancer
- Colorectal Cancer (CRC)
- Glioblastoma (GBM)
INNOVATION TAKES PERSEVERANCE & KNOWLEDGE

Commercial Innovation
Building on our market leadership, we continue to bring our promoted products to patients around the world. Our strong track record of execution is key to our success.

Developing Markets
Our research is committed to discovering and developing targeted therapies that work against the processes cancer cells need to survive. We are investigating both small and large molecule approaches, and our internal research efforts are balanced with external collaborations across industry, academia and health care authorities.

Product Launches
We develop advanced medicines that demonstrate both strong clinical performance and strong economic value. Agility and smart decision making help drive our teams to be first to market.

AbbVie Products List

Core Set of Biologies
Apoptosis: Some cancer therapies, like BCL-2 inhibitors, can help induce apoptosis, or programmed cell death, an essential natural process that eliminates damaged, unneeded or dangerous cells from the body. Dysregulation of apoptosis by cancer cells contributes to the development and progression of cancer and can lead to resistance to cancer treatments.

Targeted Cell Signaling: Interfering with the communication signals of malignant cells within tumors can be an effective way to fight cancer. BTK inhibitors block the activity of Bruton’s tyrosine kinase (BTK), which is a protein involved in the communication of signals within B cells.

DNA Damage: Cancer cells are typically hobbled with respect to DNA repair and are therefore more sensitive to DNA damage than are normal cells. Rational and targeted DNA-repair modulators, like PARP inhibitors, can be an effective way to fight cancer given the growing evidence from the early development of multiple DNA repair modulators.

Cancer Stem Cells: Cancer stem cells fuel tumor growth and spread throughout the body; understanding the biology of these cancer stem cells will guide us in developing therapies specifically targeted to destroy them.

Immuno-Oncology (I-O): I-O therapies are bringing durable and remarkable benefits to patients by utilizing the body’s immune system to help fight cancer. We believe there are many promising I-O targets (e.g., CD40, OX40) and ways of optimizing the immune response that remain to be discovered, explored and developed.

Epigenetics: Epigenetic abnormalities are frequent events implicated in the development of many types of cancer. Drugs that modulate epigenetic proteins and the architecture of DNA can influence multiple genes critical to the progression of human tumors.

Cutting-Edge Technologies
ADCs/Empowered Biologics: Our expertise in biologics and chemistry allows us to discover and develop novel molecules that deliver highly toxic drugs directly to cancer cells, allowing more effective killing of cancer cells while minimizing side effects, thus leading to more effective and safer cancer drugs.

DVD/Bipecifics: Our strength in protein engineering allows us to develop multi-specific molecules that attack the cancer from multiple angles at the same time; creating a response that is stronger than the two drugs administered simultaneously. Furthermore, it allows us to create molecules that have unique biological activities and benefits that rise from the simultaneous binding of both targets.

Small Molecules: Our expertise in chemistry allows us to design molecules that range from enzyme inhibitors to molecules that block the interactions of critical proteins. Furthermore, small molecules can be orally administered without the need to go to the hospital, thereby empowering the patient.

T-Cell Receptors: T-cell receptors can recognize aberrant peptides displayed on tumor cells. Our expertise in the engineering of human forms of T-cell receptors allows us to discover and develop next-generation cancer biologics that target tumor cells with toxic drugs or to direct immune cells to kill cancer cells.
ACCELERATING LEARNING. BUILDING CAPABILITIES.

We believe that the best way to achieve our goal of having a remarkable impact on the lives of people affected by cancer is to combine our dedicated and experienced team with innovative partnerships and collaborations that foster sharing of knowledge to deliver access to the best care for patients. We collaborate with research and academic institutions to deepen our knowledge of the core areas of biology with the goal to develop accelerated breakthroughs for cancer patients. We partner with other companies who share our commitment to oncology to strengthen our pipeline and advance the technologies aimed at striving to provide better medicines for patients.

Collaboration also allows us to work with patient associations, physician associations, payors, government and other stakeholders to explore and identify ways to provide patients with access to the best care.

We continue to look for innovative partners that complement our strengths, capabilities and commitment.

Corporate Partners

Genentech
Bristol-Myers Squibb
F-star
apogenix
Calico
janssen
argenx
CytomX Therapeutics
Seattle Genetics

Academic and Medical Center Partners

Johns Hopkins University
Northwestern University
The University of Chicago
MD Anderson Cancer Center
UCSF
AbbVie has a deep heritage in oncology research, and the technology and approaches we are taking to advance cancer treatment are becoming foundational to the next generation of cancer treatment. Our efforts combine core areas of biology with cutting-edge technologies to deliver smarter solutions faster to the oncology community.

As our pipeline grows, so does our opportunity to commercialize our products. Here is a select list of our commercialized products and a link to our active clinical trials.

**Marketed Products**

We know someone is waiting; that's why we do everything in our power to bring life-changing medicine to market the most efficient and safe way. Our products are approved in individual countries for specific uses, and the information provided is governed by local regulations. We have more than 30 products in the market.

These agents have the potential to transform the treatment of CLL, MCL and Waldenström’s macroglobulinemia.

- Monotherapy
- Combination with existing therapies
- Novel/novel combinations

**VENCLYXTA™ (venetoclax)**

- Approved by the FDA on April 2016 under accelerated approval conditions for the treatment of chronic lymphocytic leukemia
- Venetoclax is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.

On April 12, 2016, under accelerated approval conditions, the U.S. Food and Drug Administration approved venetoclax tablets, the first BCL-2 inhibitor in relapsed/refractory chronic lymphocytic leukemia patients with 17p deletion who have received at least one prior treatment. This drug is co-developed by AbbVie, Inc. and Genentech USA, Inc.

**EMPLICITI™ (elotuzumab)**

- Approved by the FDA on November 2015 for the treatment of multiple myeloma
- Approved by the European Commission on May 2016 for the treatment of multiple myeloma under accelerated approval conditions
- Bristol-Myers Squibb and AbbVie are co-developing Empliciti, with Bristol-Myers Squibb solely responsible for commercial activities

The U.S. Food and Drug Administration has approved elotuzumab in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. This drug is co-developed by AbbVie, Inc. and Bristol-Myers Squibb.

EMPLICITI™ (elotuzumab) is a humanized monoclonal antibody directed against SLAMF7. EMPLICITI™ was approved by the U.S. Food and Drug Administration in 2015 for the treatment of multiple myeloma in combination with the medicines REVLIMID® (lenalidomide) and dexamethasone in people who have received one to three prior treatments for their multiple myeloma.
Mechanism of Action
Elotuzumab is a humanized monoclonal antibody directed against SLAMF7, a cell-surface glycoprotein that is highly and uniformly expressed on multiple myeloma cells but is minimally expressed on normal cells.

Development & Ongoing Clinical Trials
AbbVie and Bristol-Myers Squibb jointly developed elotuzumab. In addition to the approved indication, AbbVie and BMS have ongoing clinical trials to assess elotuzumab in multiple myeloma.

IMBRUVICA® (ibrutinib)
- Approved by the FDA in November 2013 for mantle cell lymphoma
- Approved by the FDA in February 2014 for chronic lymphocytic leukemia
- The FDA expanded the approved use in January 2015 for Waldenström's macroglobulinemia
- Approved by the FDA in March 2016 for first-line treatment of chronic lymphocytic leukemia
- The FDA expanded the approved use in May 2016 for small lymphocytic lymphoma
- Approved by the FDA in January 2017 as a first treatment for marginal zone lymphoma
- Approved by the FDA in August 2017 for adult patients with Chronic Graft-Versus-Host-Disease
- Imbruvica is commercialized and developed by Janssen Biotech, Inc., and Pharmacyclics, a wholly owned subsidiary of AbbVie

Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, together with Janssen Biotech, Inc., developed and commercialize IMBRUVICA® (ibrutinib), a first-in-class, oral, once-daily medication that inhibits a protein called Bruton's tyrosine kinase (BTK). BTK is a key signaling molecule in the B-cell receptor that plays an important role in the survival and spread of malignant B cells. IMBRUVICA blocks signals that tell malignant B cells to multiply and spread uncontrollably.

IMBRUVICA has eight U.S. Food and Drug Administration approvals across six disease indications. IMBRUVICA has also been granted four Breakthrough Therapy Designations (BTD) by the FDA, more than any other medication to date. BTDs are granted on a special basis by the FDA for medical conditions that have limited treatment options and where the immediate need for safe and effective therapies is great.

We are committed to fully exploring the potential of ibrutinib and its unique mechanism of action (MOA) across hematological oncology and other disease states.
Late-Stage Investigational Compounds

**Veliparib**
Veliparib is an investigational oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor AbbVie is evaluating in multiple tumor types.

**ABT-414**
ABT-414 is an investigational EGFR (epidermal growth factor receptor) targeted monoclonal antibody drug conjugate being studied in gliobastoma.

**ROVA-T**
Rova-T (rovalpituzumab tesirine) is an investigational antibody drug conjugate targeting the cancer stem cell-associated target delta-like protein 3 (DLL3). It is also being investigated as a combination therapy with Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a second-line treatment for extensive-stage small cell lung cancer (SCLC).

Early-Stage Investigational Compounds

**ABT-621**
ABT-621 is a first-in-class, second generation TRAIL-receptor agonist under development for the treatment of solid and hematologic tumors.

**ABT-165**
ABT-165 is an investigational Dual Variable Domain Immunoglobulin (DVD-Ig™) that inhibits VEGF (vascular endothelial growth factor) and DLL4 (delta like ligand 4), which can potentially suppress tumor angiogenesis and tumor initiating cells. ABT-165 is being studied in Phase 1 trials. ABT-165 is in clinical trials for the treatment of patients with advanced solid tumors.

**Telisotuzumab Vedotin (ABBV-399)**
ABBV-399 is an investigational antibody drug conjugate (ADC) targeting cMet that is being studied in a Phase 1 clinical trial in patients with solid tumors.
Explore Career Opportunities

We are scientists, researchers, sales professionals, marketers, communicators, manufacturing specialists and regulatory experts, but we are also parents, brothers, sisters, friends, community leaders, volunteers and more. We have a lot in common with the people we serve, and we come together every day with a unified passion to create, discover and deliver new ways to help improve people's health and address areas of unmet need in oncology.

Visit www.abbvieoncology.com for more information.
“Working at AbbVie means being committed to the patient and being dedicated to excellence. If you want to work at a place that really does give you the chance to make a meaningful impact on cancer patients, then this is the place. Our strong oncology pipeline and commitment of R&D dollars specific to oncology is incredibly exciting to our ability to continue to impact cancer patients for many years to come.”

— William Vollmer, MPH, Oncology Sales Director